OrbiMed Capital GP VI LLC's Net Worth

$1.07 Billion

Estimate Recalculated Mar 1, 2024 08:23PM EST

Who is OrbiMed Capital GP VI LLC?

OrbiMed Capital GP VI LLC has an estimated net worth of $1.07 Billion. This is based on reported shares across multiple companies, which include Adicet Bio, Inc., LogicBio Therapeutics, Inc., 89bio, Inc., SteadyMed Ltd., AVEDRO INC, Turning Point Therapeutics, Inc., CONSTELLATION PHARMACEUTICALS INC, Prelude Therapeutics Inc, Crinetics Pharmaceuticals, Inc., Verona Pharma plc, ALPINE IMMUNE SCIENCES, INC., CTI BIOPHARMA CORP, NeuroPace Inc, Edgewise Therapeutics, Inc., Ikena Oncology, Inc., ARVINAS INC., Prevail Therapeutics Inc., ARS Pharmaceuticals, Inc., Disc Medicine, Inc., GRAYBUG VISION, INC., Oric Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., scPharmaceuticals Inc., NextCure, Inc., SYNLOGIC, INC., SpringWorks Therapeutics, Inc., and Turnstone Biologics Corp..

SEC CIK

OrbiMed Capital GP VI LLC's CIK is 0001682115

Past Insider Trading and Trends

2020 was OrbiMed Capital GP VI LLC's most active year for acquiring shares with 31 total transactions. OrbiMed Capital GP VI LLC's most active month to acquire stocks was the month of December. 2021 was OrbiMed Capital GP VI LLC's most active year for disposing of shares, totalling 49 transactions. OrbiMed Capital GP VI LLC's most active month to dispose stocks was the month of February. 2020 saw OrbiMed Capital GP VI LLC paying a total of $111,888,105.01 for 64,654,696 shares, this is the most they've acquired in one year. In 2021 OrbiMed Capital GP VI LLC cashed out on 48,733,244 shares for a total of $137,125,898.41, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Adicet Bio, Inc. (ACET) Snapshot price: $3.215

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+47.01%
3.13M
$2.40
$7,500,000.00
9.77M
Jan 25
Form 4
+12.10%
875K
$2.09
$1,828,750.00
8.11M
Jun 27
Form 4
+765.30%
214.28K
$14.00
$2,999,990.00
242.28K
Dec 10
Form 4
+10.25%
524.35K
$13.00
$6,816,537.00
5.64M
Feb 12
Form 4
6.02M
6.02M
Sep 15 - Sep 17
Form 4
4.83M
$15.00
4.83M
Jan 30
Form 3
0
0
No matching records found

AVEDRO INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+2,681.91%
4.09M
4.24M
Feb 19
Form 3
0
0
No matching records found

Turning Point Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.03M
$18.00
2.03M
Apr 22
Form 3
0
0
No matching records found

CONSTELLATION PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
835.84K
$15.00
835.84K
Jul 23
Form 3
0
0
No matching records found

Prelude Therapeutics Inc (PRLD) Snapshot price: $2.92

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+9.40%
869.57K
$5.75
$4,999,998.75
10.12M
May 22
Form 4
0
0
Jan 11
Form 4/A
0
0
Mar 27 - Aug 21
Form 4
+4,624.95%
9.57M
$19.00
$9,999,700.00
9.78M
Sep 25 - Sep 29
Form 3
0
0
No matching records found